BERKELEY HEIGHTS, N.J., March 5, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced publication of an investigator-sponsored Phase 1 study reporting pharmacodynamic effects of seliciclib, an orally-administered cell cycle modulator, in treatment-naive patients with undifferentiated nasopharyngeal cancer. The data were published in the February 2009 issue of the journal Clinical Cancer Research. The study was led by Boon-Cher Goh, MD and colleagues at National University Hospital, Singapore. Seliciclib, Cyclacel's orally available cyclin dependent kinase (CDK) inhibitor, is currently being evaluated in two randomized Phase 2 trials in patients with previously treated nasopharyngeal and non-small cell lung cancer.
